maximum weight loss tirzepatide surmount trials Presented today at #ECO2026 ⤵️ The SURMOUNT-MAINTAIN trial found that continuing at the tolerated dose maintained bodyweight reduction and health-related benefits in adults with obesity. Explore the research: https://t.co/RjLxWa5qjV Tirzepatide for Obesity: Highlights from

Description

For others, factors like genetics and hormones work against them, placing additional obstacles in their path to success

Every patient gets a complete weight loss plan built around their specific health history, their goals, and their lifestyle

Retatrutide represents the next frontier

Clinical data shows women typically lose a higher percentage of body weight than men, ranging from 11.5% to 27.6% for women versus 8.8% to 18.9% for men

Microdosing is most commonly used by people who are sensitive to medications, have a history of GI issues, or had previous difficulty tolerating GLP-1 agonists